Anik

BigNick

Siamo solo noi
Registrato
10/7/01
Messaggi
11.738
Punti reazioni
1.140
entrato oggi con poco, domani mattina gli earnings, una scommessa, graficamente sembrerebbe bella

attendo domani

bye

BigNick
 

Allegati

  • anik1.gif
    anik1.gif
    24,3 KB · Visite: 358
ciao big sei entrato seguendo un segnale di at se si quale(x me è algebra) o altro
 
ho cercato di anticipare

Scritto da ciches
ciao big sei entrato seguendo un segnale di at se si quale(x me è algebra) o altro

occhio perchè il rischio è alto qui

Grafico weekly
 

Allegati

  • anik2.gif
    anik2.gif
    29,2 KB · Visite: 355
e questo è il Montly

bello anche questo
 

Allegati

  • anik3.gif
    anik3.gif
    26,7 KB · Visite: 351
ANIK

News) today announced that revenue for the first quarter ending March 31, 2003, rose 42% to $3,384,000 from $2,390,000 for the same period last year. The company reported a net loss for the quarter of $313,000, or $.03 per share, compared with a loss of $1,804,000, or $.18 per share, for the first quarter of 2002.
 
Anika Therapeutics Announces First Quarter Financial Results

Anika Therapeutics Announces First Quarter Financial Results
Tuesday May 6, 8:15 am ET


WOBURN, Mass.--(BUSINESS WIRE)--May 6, 2003--Anika Therapeutics, Inc. (Nasdaq:ANIK - News) today announced that revenue for the first quarter ending March 31, 2003, rose 42% to $3,384,000 from $2,390,000 for the same period last year. The company reported a net loss for the quarter of $313,000, or $.03 per share, compared with a loss of $1,804,000, or $.18 per share, for the first quarter of 2002.

Charles H. Sherwood, Ph.D., president and chief executive officer, said higher ophthalmic product sales with the addition of a new customer in May 2002 contributed to revenue growth for the quarter. Sales of HYVISC®, a treatment for equine osteoarthritis, were also up on a quarter-over-quarter basis, due in part to distributor inventory replenishment for certain units shipped without required regulatory approval in the latter part of 2002, as Anika previously reported.

Anika's gross profit for the quarter was 42% of sales versus 13% for the first quarter of 2002, mostly reflecting increased unit volumes combined with manufacturing efficiency gains achieved during 2002. Research and development expenses totaled approximately $809,000 versus $1,090,000 for the comparable 2002 quarter, a period of high patient accrual for Anika's ORTHOVISC clinical trial. Selling, general and administrative expenses were $1,115,000 compared with $1,080,000 for the same period last year. Results for the first quarter also included a non-recurring tax refund of $154,000. Anika's cash and short-term investments at March 31, 2003 totaled $13.0 million compared with $13.5 million at December 31, 2002 and $12.4 million at March 31, 2002.

"Right now we are very focused on conducting the final analyses of our ORTHOVISC Phase III human clinical trial data in preparation for filing a submission with the Food & Drug Administration for U.S. market approval," Sherwood said. "We also are hard at work toward adding international marketing and distribution partners for ORTHOVISC and narrowing in on a potential U.S. marketing partner."

Sherwood noted that Anika plans to increase expenditures in 2003 on marketing its current products and on potential clinical trials for therapies in its product pipeline.

Conference Call Information

The company will hold a conference call to review its financial results today at 11:00 a.m. EDT. To listen to the conference call, dial (706) 634-1550 approximately 10 minutes before the starting time and reference Anika Therapeutics. The call can also be accessed through a live Internet broadcast at Anika's Web site, http://www.anikatherapeutics.com/newset.htm. The call will be archived at the same Web site beginning at 2 p.m. today for one year through May 6, 2004.

About Anika Therapeutics, Inc.

Headquartered in Woburn, Mass., Anika Therapeutics, Inc. (www.anikatherapeutics.com) develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body.
 
Cercavo di essere più....sintetico...:D:D:D:D.
Non male direi comunque.....
 
Scritto da kgb
Cercavo di essere più....sintetico...:D:D:D:D.
Non male direi comunque.....


mi sembra interessante questo pezzo:

Right now we are very focused on conducting the final analyses of our ORTHOVISC Phase III human clinical trial data in preparation for filing a submission with the Food & Drug Administration for U.S. market approval," Sherwood said. "We also are hard at work toward adding international marketing and distribution partners for ORTHOVISC and narrowing in on a potential U.S. marketing partner."
 
Pensa che io invece avevo focalizzato la mia attenzione su Hyvisc il farmaco che producono per l'osteoartrosi equina...chissà se va bene per i trader-umani,io ne avrei bisogno:D:D:D:D:D.
 
CC

live today at 11:00 am ET)

a che ora corrisponde ?
 
le nostre 17 direi.
 
vediamo cosa ci raccontano

Scritto da kgb
le nostre 17 direi.

intanto dopo il botto iniziale stà stornando a 2,65...
 
metà (ne avevo 3000 a 2,54) le ho vendute all'inizio a 2,86,le altre attendo.
 
Dai che forse partono...

2,98 Var% 18,21%

non so cosa stiano dicendo nella cc ma sembra che faccia bene al titolo :)
 
io la cc non la sento perchè win.media player non mi funzia...comunque ho scaricato le ultime 1500 a 2,97 e va benissimo così!!
 
le hai chiamate Lucky ?

+ 12,61%

:)
 
ciao big,ciao luciano :sei entrato big? ma i volumi sono sempre cosi bassi o il mio streamer sbaglia qualcosa 38.150 si entra sullo storno $2.43
 
r

Scritto da ciches
ciao big,ciao luciano :sei entrato big? ma i volumi sono sempre cosi bassi o il mio streamer sbaglia qualcosa 38.150 si entra sullo storno $2.43

io sono dentro, se guardi il primo post..

in effetti volumi bassissimi, guardati i grafici che ho postato e poi decidi con la tua testa

ciao

BigNick
 
oggi parte bene..

..i volumi però non esistono

BigNick
 
Indietro